Evidence map›Paper›PMID 41973603›Full record

Observational studyEuropean thyroid journal2026

Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers.

Edoardo Talpacci, Manuela Macera, Giulia Maida, Silvia Morelli, Vincenzo Leone, Chiara Ingriccini, Antonella Ferrieri, Rachele Tortoriello, Miriam Paci, Monia Baldoni and 7 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Edoardo TalpacciDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Manuela MaceraDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Giulia MaidaDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Silvia MorelliDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Vincenzo LeoneDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Chiara IngricciniDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Antonella FerrieriDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Rachele TortorielloDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Miriam PaciDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Monia BaldoniDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Olivia MorelliDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Samuele BarpDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Marialuisa SponzielloDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Marianna MaranghiDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Cosimo DuranteDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-1791-5915
Giorgio GraniDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-0388-1283
Efisio PuxedduDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.ORCID 0000-0001-9611-6216

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Anaplastic thyroid carcinoma (ATC) is an extremely aggressive cancer, traditionally refractory to conventional treatments. The combined therapy with lenvatinib and pembrolizumab (L + P) is supported by a preclinical rationale based on the distinctive immunological profile of ATC. We propose a real-life study to evaluate relevant clinical outcomes and identify survival predictors in a cohort of ATC patients treated with the combined therapy in two Italian referral centers. Methods: Sixteen ATC patients treated with the combination of L + P were retrospectively included. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) were assessed according to RECIST 1.1 criteria. Baseline patient characteristics, including immuno-nutritional status (calculated using the CONUT score), were analyzed to identify potential predictors of response. Results: A median OS of 10 months (95% CI: 4.2-15.9 months) and a median PFS of 6.0 months (95% CI: 0-12.7 months) were observed after L + P therapy. Complete response was observed in 6.2% and partial response in 31.3% of patients, resulting in an ORR of 37.5%; the DCR was 68.8%. Progressive disease occurred in 25% of patients. Furthermore, a baseline CONUT score ≤ 2 resulted in a significantly longer OS (log-rank, P = 0.001) and PFS (P = 0.05) compared to CONUT score ≥ 3, while a non-significantly longer OS was observed between patients with a baseline ECOG PS of 0-2 and those with a baseline ECOG PS ≥ 3. Conclusion: Our study confirms the efficacy and safety of L + P therapy, identifying the CONUT score as a prognostic factor.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsPhenylurea CompoundsQuinolinesThyroid Carcinoma, AnaplasticThyroid NeoplasmsAgedAged, 80 and overFemaleHumansItalyMaleMiddle AgedProgression-Free SurvivalRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedlenvatinibpembrolizumabPhenylurea CompoundsQuinolinesanaplastic thyroid carcinomacombination treatmentlenvatinibpembrolizumab

Identifiers

PMID41973603
PMCPMC13178430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.